Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.

Ann Clin Transl Neurol · 2026 · PMC13071087 · PMID 41236176

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Notably, UTI incidence appeared numerically higher in the satralizumab group at 24 and 36 months, although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.